Invasive Pulmonary Aspergillosis in Hospitalized Hematopoietic Stem Cell Transplantation Recipients: Outcomes Based on The United States National Readmission Database

Amir Khalil, Department of Internal Medicine, Wayne State University. Detroit, MI. USA.
Paramveer Singh, Division of Hematology and Oncology, Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA
Tanveer Mir, Department of Internal Medicine, Wayne State University. Detroit, MI. USA.
Mohammed Uddin, Department of Internal Medicine, Wayne State University. Detroit, MI. USA.
Ayman O. Soubani, Division of Pulmonary and Critical Care Medicine, Wayne State University. Detroit, MI. USA.Follow

Abstract

Background and Objective: Hematopoietic Stem Cell Transplant (HSCT) is well established treatment for hematologic malignancies and certain autoimmune and congenital conditions. HSCT is associated with immunocompromise and increased risk of infections. Our primary objective was to assess whether invasive pulmonary aspergillosis (IPA) affects in-hospital mortality and 30-day readmission among patients undergoing HSCT. A secondary objective was to examine potential differences in complications between HSCT with IPA and HSCT without IPA. Materials and Methods: A retrospective study of a nationally representative cohort of hospital admissions was conducted, with data collected from the Agency for Healthcare Research and Quality's Healthcare Cost and Utilization Project (HCUP) Nationwide Readmissions Database (NRD) between 2013 and 2019. We used the International Classification of Diseases, 10th revision (ICD–10), and 9th revision (ICD-9) diagnostic codes to identify patients with IPA and HSCT. All adult patients ≥18 years were included in the study.

Results: There were 90,451 hospitalizations for HSCT from 2013-2019. 89,331 (98.8%) had HSCT without IPA, while 1,092 (1.2%) hospitalizations had HSCT with IPA. The in-hospital mortality for HSCT-IPA was higher compared to HSCT without IPA (18.3% vs 4.2%; p

The HSCT-IPA group had higher multi-organ complications including respiratory failure (51.3% vs 13.5%, p

Conclusion: IPA is rare but serious complication associated with HSCT, with higher in-hospital mortality, complications due to multiorgan failure, readmission rates, and cost of hospitalization when compared to HSCT without IPA.

Recommended Citation

Khalil, Amir; Singh, Paramveer; Mir, Tanveer; Uddin, Mohammed; and Soubani, Ayman O. (2023) "Invasive Pulmonary Aspergillosis in Hospitalized Hematopoietic Stem Cell Transplantation Recipients: Outcomes Based on The United States National Readmission Database," Hematology/Oncology and Stem Cell Therapy: Vol. 17 : Iss. 1 , Article 5.
Available at: https://doi.org/10.56875/2589-0646.1109